Neuropharmacology of the interoceptive stimulus properties of nicotine

Current Drug Abuse Reviews

Volumn 2, Issue 3, 2009, Pages 243-255

  Wooters, Thomas E ^a   Bevins, Rick A ^b   Bardo, Michael T ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Conditional stimulus; Drug discrimination; Nicotine; Nicotinic acetylcholine receptor

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; ADENOSINE; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; CANNABINOID; DEXTROMETHORPHAN; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORT INHIBITOR; DOPAMINE UPTAKE INHIBITOR; ETICLOPRIDE; MECAMYLAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; RIMONABANT; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE;

ARTICLE; CONDITIONING; DISCRIMINATIVE STIMULUS; DOPAMINE RELEASE; DRUG DISCRIMINATION; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HIPPOCAMPUS; LONG TERM EXPOSURE; MESENCEPHALON RETICULAR FORMATION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REINFORCEMENT; VENTRAL TEGMENTUM;

ANIMALS; DISCRIMINATION LEARNING; HUMANS; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; REINFORCEMENT (PSYCHOLOGY); TOBACCO USE DISORDER;

EID: 77951542294     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473710902030243     Document Type: Article

References (177)

1. Appel JB, West WB, Buggy J. LSD, 5-HT (serotonin), and the evolution of a behavioral assay. Neurosci Biobehav Rev 2004; 27: 693-1.
2. Balster RL. Drug abuse potential evaluation in animals. Br J Addict 1991; 86: 1549-58.
3. Thompson T, Pickens R. Stimulus properties of drugs. New York: Plenum Press 1971.
4. Overton DA. In: Glennon RA, Jarbe TUC, Frankenheim J, Eds. Drug discrimination: applications to drug abuse research. Washington, DC., U.S. DHHS 1991; 5-24.
5. Colpaert FC. In: Bozarth MA, Ed. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag 1987; 341-72.
6. Colpaert FC. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1999; 64: 337-45.
7. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc 2006; 1: 1194-6.
8. Stolerman IP. Drug discrimination. In: van Haaren F, Ed. Methods in behavioral pharmacology. Amsterdam: Elsevier 1993; 217-43.
9. Bevins RA. Altering the motivational function of nicotine through conditioning processes. Nebr Symp Motiv 2009; 55: 111-29.
10. Farwell BJ, Ayres JJB. Stimulus-reinforcer and response-reinforcer relations in the control of conditioned appetitive headpoking ("goal tracking") in rats. Learn Motiv 1979; 10: 295-12.
11. Besheer J, Palmatier MI, Metschke DM, Bevins RA. Nicotine as a signal for the presence or absence of sucrose reward: a Pavlovian drug appetitive conditioning preparation in rats. Psychopharmacology 2004; 172: 108-17.
12. Bevins RA, Wilkinson JL, Palmatier MI, Siebert HL, Wiltgen SM. Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats. Psychopharmacology (Berl) 2006; 184: 470-81.
13. Palmatier MI, Peterson JL, Wilkinson JL, Bevins RA. Nicotine serves as a feature-positive modulator of Pavlovian appetitive conditioning in rats. Behav Pharmacol 2004; 15: 183-94.
14. Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith BJ. Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology (Berl) 1993; 111: 259-70.
15. Smith JW, Stolerman IP. Recognising nicotine: the neurobiological basis of nicotine discrimination. Handb Exp Pharmacol 2009; 295-333.
16. Morrison CF, Stephenson JA. Nicotine injections as the conditioned stimulus in discrimination learning. Psychopharmacologia 1969; 15: 351-60.
17. Rosecrans JA. Nicotine as a discriminative stimulus to behavior: its characterization and relevance to smoking behavior. NIDA Res Monogr 1979; 58-69.
18. Schechter MD, Rosecrans JA. C.N.S. effect of nicotine as the discriminative stimulus for the rat in a T-maze. Life Sci 1971; 10: 821-32.
19. Quarta D, Naylor CG, Barik J, Fernandes C, Wonnacott S, Stolerman IP. Drug discrimination and neurochemical studies in alpha7 null mutant mice: tests for the role of nicotinic alpha7 receptors in dopamine release. Psychopharmacology (Berl) 2009; 203: 399-410.
20. Damaj MI, Glassco W, Marks MJ, et al. Pharmacological investigation of (+)-and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo-[3,2-h]isoquinoline, a bridged-nicotine analog. J Pharmacol Exp Ther 1997; 282: 1425-34.
21. Dwoskin LP, Wooters TE, Sumithran SP, et al. N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity. J Pharmacol Exp Ther 2008; 326: 563-76.
22. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann Rev Pharmacol Toxicol 2007; 47: 699-727.
23. Desai RI, Barber DJ, Terry P. Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine. Behav Pharmacol 1999; 10: 647-56.
24. Damaj MI, Creasy KR, Grove AD, Rosecrans JA, Martin BR. Pharmacological effects of epibatidine optical enantiomers. Brain Res 1994; 664: 34-40.
25. Hazell P, Peterson DW, Laverty R. Brief communication. Inability of hexamethonium to block the discriminative stimulus (SD) property of nicotine. Pharmacol Biochem Behav 1978; 9: 137-40.
26. Stolerman IP, Garcha HS, Pratt JA, Kumar R. Role of training dose in discrimination of nicotine and related compounds by rats. Psychopharmacology (Berl) 1984; 84: 413-9.
27. Stolerman IP, Kumar R, Reavill C. Discriminative stimulus effects of cholinergic agonists and the actions of their antagonists. Psychopharmacol Ser 1988; 4: 32-43.
28. Kumar R, Reavill C, Stolerman IP. Nicotine cue in rats: effects of central administration of ganglion-blocking drugs. Br J Pharmacol 1987; 90: 239-46.
29. Gasior M, Shoaib M, Yasar S, Jaszyna M, Goldberg SR. Acquisition of nicotine discrimination and discriminative stimulus effects of nicotine in rats chronically exposed to caffeine. J Pharmacol Exp Ther 1999; 288: 1053-73.
30. Murray JE, Bevins RA. Acquired appetitive responding to intravenous nicotine reflects a Pavlovian conditioned association. Behav Neurosci 2009; 123: 97-108.
31. Rosecrans JA. Nicotine as a discriminative stimulus: a neurobiobehavioral approach to studying central cholinergic mechanisms. J Subst Abuse 1989; 1: 287-300.
32. Jung M, Costa L, Shearman GT, Kelly PH. Discriminative stimulus properties of muscarinic agonists. Psychopharmacology (Berl) 1987; 93: 139-45.
33. Locke KW, Gorney B, Cornfeldt M, Fielding S. Characterization of the discriminative stimulus effects of physostigmine in the rat. J Pharmacol Exp Ther 1989; 250: 241-6.
34. Meltzer LT, Rosecrans JA. Discriminative stimulus properties of arecoline: a new approach for studying central muscarinic receptors. Psychopharmacology (Berl) 1981a; 75: 383-7.
35. Jung M, Perio A, Worms P, Soubrie P. Pharmacological characterization of the physostigmine stimulus in rats. Psychopharmacology (Berl) 1988; 95: 553-5.
36. Tang AH, Franklin SR. Discriminative stimulus properties of physostigmine in rats. Eur J Pharmacol 1988; 153: 97-104.
37. Meltzer LT, Rosecrans JA. Nicotine and arecoline as discriminative stimuli: involvement of a non-cholinergic mechanism for nicotine. Pharmacol Biochem Behav 1988; 29: 587-93.
38. Bardo MT, Bevins RA, Klebaur JE, Crooks PA, Dwoskin LP. (-)-Nornicotine partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacol Biochem Behav 1997; 58: 1083-7.
39. Brioni JD, Kim DJ, O'Neill AB, Williams JE, Decker MW. Clozapine attenuates the discriminative stimulus properties of (-)-nicotine. Brain Res 1994; 643: 1-9.
40. Chance WT, Kallman MD, Rosecrans JA, Spencer RM. A comparison of nicotine and structurally related compounds as discriminative stimuli. Br J Pharmacol 1978; 63: 609-16.
41. Goldberg SR, Risner ME, Stolerman IP, Reavill C, Garcha HS. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology (Berl) 1989; 97: 295-2.
42. Pratt JA, Stolerman IP, Garcha HS, Giardini V, Feyerabend C. Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor. Psychopharmacology (Berl) 1983; 81: 54-60.
43. Reavill C, Spivak CE, Stolerman IP, Waters JA. Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats. Neuropharmacology 1987; 26: 789-92.
44. Reavill C, Waters JA, Stolerman IP, Garcha HS. Behavioural effects of the nicotinic agonists N-(3-pyridylmethyl)pyrrolidine and isoarecolone in rats. Psychopharmacology (Berl) 1990; 102: 521-8.
45. Stolerman IP, Albuquerque EX, Garcha HS. Behavioural effects of anatoxin, a potent nicotinic agonist, in rats. Neuropharmacology 1992; 31: 311-4.
46. Takada K, Swedberg MD, Goldberg SR, Katz JL. Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys. Psychopharmacology (Berl) 1989; 99: 208-12.
47. Chandler CJ, Stolerman IP. Discriminative stimulus properties of the nicotinic agonist cytisine. Psychopharmacology (Berl) 1997; 129: 257-64.
48. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 1992; 41: 31-7.
49. Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux JP. The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 2002; 42: 530-9.
50. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48: 3474-7.
51. Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003; 306: 407-20.
52. Craft RM, Howard JL. Cue properties of oral and transdermal nicotine in the rat. Psychopharmacology (Berl) 1988; 96: 281-4.
53. LeSage MG, Shelley D, Ross JT, Carroll FI, Corrigall WA. Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats. Pharmacol Biochem Behav 2009; 91: 461-7.
54. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007; 28: 316-25.
55. Brioni JD, Kim DJ, Brodie MS, Decker MW, Arneric SP. ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology (Berl) 1995; 119: 368-75.
56. Smith JW, Mogg A, Tafi E, et al. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 2007; 190: 157-70.
57. Xiao Y, Woolverton WL, Sahibzada N, Yasuda RP, Kellar KJ. Pharmacological properties of sazetidine-A, a desensitizer of alpha4beta2 nicotinic acetylcholine receptors. 2007 San Diego, Neuroscience Meeting Planner. Program No. 574.6/J11.
58. Picciotto MR, Addy NA, Mineur YS, Brunzell DH. It's not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 2008; 84: 329-42.
59. Meltzer LT, Rosecrans JA, Aceto MD, Harris LS. Discriminative stimulus properties of the optical isomers of nicotine. Psychopharmacology (Berl) 1980; 68: 283-6.
60. Martin BR, Aceto MD. Nicotine binding sites and their localization in the central nervous system. Neurosci Biobehav Rev 1981; 5: 473-8.
61. Gommans J, Stolerman IP, Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 2000; 39: 2840-7.
62. Shoaib M, Zubaran C, Stolerman IP. Antagonism of stimulus properties of nicotine by dihydro-beta-erythroidine (DHbetaE) in rats. Psychopharmacology (Berl) 2000; 149: 140-6.
63. Stolerman IP, Chandler CJ, Garcha HS, Newton JM. Selective antagonism of behavioural effects of nicotine by dihydro-beta-erythroidine in rats. Psychopharmacology (Berl) 1997; 129: 390-7.
64. Zaniewska M, McCreary AC, Przegalinski E, Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 2006; 540: 96-6.
65. Mansbach RS, Chambers LK, Rovetti CC. Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine. Psychopharmacology (Berl) 2000; 148: 234-42.
66. Champtiaux N, Han ZY, Bessis A, et al. Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice. J Neurosci 2002; 22: 1208-17.
67. Grady SR, Salminen O, Laverty DC, et al. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochem Pharmacol 2007; 74: 1235-46.
68. Salminen O, Drapeau JA, McIntosh JM, Collins AC, Marks MJ, Grady SR. Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice. Mol Pharmacol 2007; 71: 1563-71.
69. Cartier GE, Yoshikami D, Gray WR, Luo S, Olivera BM, McIntosh JM. A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors. J Biol Chem 1996; 271: 7522-8.
70. Exley R, Clements MA, Hartung H, McIntosh JM, Cragg SJ. Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology 2008; 33: 2158-66.
71. Pons S, Fattore L, Cossu G, et al. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 2008; 28: 12318-27.
72. Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) 2006; 184: 426-34.
73. Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 2007; 52: 755-63.
74. Wooters TE, Ross JT, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT. Effects of the nicotinic acetylcholine receptor antagonist, N,N'-decane-1,10-diyl-bis-3-picolinium diiodide, on nicotine self-administration and food-maintained responding in rats. College on the Problems of Drug Dependence Program Book 2008; 13.
75. Struthers AM, Wilkinson JL, Dwoskin LP, Crooks PA, Bevins RA. Nicotinic acetylcholine antagonism of the conditional stimulus effects of nicotine. Eur J Pharmacol 2009; (submitted).
76. Wright MJ Jr., Vann RE, Gamage TF, Damaj MI, Wiley JL. Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats. Pharmacol Biochem Behav 2006; 85: 507-13.
77. Zakharova ES, Danysz W, Bespalov AY. Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats. Psychopharmacology (Berl) 2005; 179: 128-35.
78. Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L. The role of nicotinic receptor alpha 7 subunits in nicotine discrimination. Neuropharmacology 2004; 46: 363-71.
79. van Haaren F, Anderson KG, Haworth SC, Kem WR. GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 1999; 64: 439-44.
80. Brioni JD, Kim DJ, O'Neill AB. Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 1996; 301: 1-5.
81. Bardo MT. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998; 12: 37-67.
82. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 1998; 28: 309-69.
83. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002; 53: 606-17.
84. Palmatier MI, Bevins RA. Examination of GABAergic and dopaminergic compounds in the acquisition of nicotine-conditioned hyperactivity in rats. Neuropsychobiology 2002; 45: 87-94.
85. Wise RA. Forebrain substrates of reward and motivation. J Comp Neurol 2005; 493: 115-21.
86. Corrigall WA, Coen KM. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 1991; 104: 171-6.
87. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393: 295-14.
88. Shoaib M. Is dopamine important in nicotine dependence? J Physiol Paris 1998; 92: 229-33.
89. Mansbach RS, Rovetti CC, Freedland CS. The role of monoamine neurotransmitter systems in the nicotine discriminative stimulus. Drug Alcohol Depend 1998; 52: 125-34.
90. Reavill C, Stolerman IP. Interaction of nicotine with dopaminergic mechanisms assessed through drug discrimination and rotational behaviour in rats. J Psychopharmacol 1987; 1: 264-73.
91. Corrigall WA, Coen KM. Dopamine mechanisms play at best a small role in the nicotine discriminative stimulus. Pharmacol Biochem Behav 1994; 48: 817-20.
92. Murray JE, Bevins RA. Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus. Eur J Pharmacol 2007; 561: 91-4.
93. Schechter MD, Meehan SM. Dopaminergic mediation of the stimulant generalization of nicotine. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 835-45.
94. Gatch MB, Flores E, Forster MJ. Nicotine and methamphetamine share discriminative stimulus effects. Drug Alcohol Depend 2008; 93: 63-71.
95. Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005; 30: 720-30.
96. de la Garza R, Johanson CE. Discriminative stimulus properties of cocaine in pigeons. Psychopharmacology (Berl) 1985; 85: 23-30.
97. Takada K, Hagen TJ, Cook JM, Goldberg SR, Katz JL. Discriminative stimulus effects of intravenous nicotine in squirrel monkeys. Pharmacol Biochem Behav 1988; 30: 243-7.
98. Desai RI, Barber DJ, Terry P. Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology (Berl) 2003; 167: 335-43.
99. Reichel CM, Linkugel JD, Bevins RA. Nicotine as a conditioned stimulus: impact of attention-deficit/hyperactivity disorder medications. Exp Clin Psychopharmacol 2007; 15: 501-9.
100. Damaj MI, Slemmer JE, Carroll FI, Martin BR. Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs. J Pharmacol Exp Ther 1999; 289: 1229-36.
101. Cunningham CS, Polston JE, Jany JR, Segert IL, Miller DK. Interaction of lobeline and nicotinic receptor ligands with the discriminative stimulus properties of cocaine and amphetamine. Drug Alcohol Depend 2006; 84: 211-22.
102. Garza RD, Johanson CE. The discriminative stimulus properties of cocaine in the rhesus monkey. Pharmacol Biochem Behav 1983; 19: 145-8.
103. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-7.
104. Wilkinson JL, Li C, Bevins RA. Pavlovian drug discrimination with bupropion as a feature positive occasion setter: substitution by methamphetamine and nicotine, but not cocaine. Addict Biol 2009; 14: 165-73.
105. Wiley JL, Lavecchia KL, Martin BR, Damaj MI. Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 2002; 10: 129-35.
106. Young R, Glennon RA. Nicotine and bupropion share a similar discriminative stimulus effect. Eur J Pharmacol 2002; 443: 113-8.
107. Shoaib M, Sidhpura N, Shafait S. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology (Berl) 2003; 165: 405-12.
108. Bondarev ML, Bondareva TS, Young R, Glennon RA. Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 2003; 474: 85-93.
109. Wooters TE, Neugebauer NM, Rush CR, Bardo MT. Methylphenidate enhances the abuse-related behavioral effects of nicotine in rats: intravenous self-administration, drug discrimination, and locomotor cross-sensitization. Neuropsychopharmacology 2008a; 33: 1137-48.
110. Chance WT, Murfin D, Krynock GM, Rosecrans JA. A description of the nicotine stimulus and tests of its generalization to amphetamine. Psychopharmacology (Berl) 1977; 55: 19-26.
111. Stolerman IP. Discriminative stimulus effects of nicotine in rats trained under different schedules of reinforcement. Psychopharmacology (Berl) 1989; 97: 131-8.
112. Varvel SA, James JR, Bowen S, Rosecrans JA, Karan LD. Discriminative stimulus (DS) properties of nicotine in the C57BL/6 mouse. Pharmacol Biochem Behav 1999; 63: 27-32.
113. Palmatier MI, Wilkinson JL, Metschke DM, Bevins RA. Stimulus properties of nicotine, amphetamine, and chlordiazepoxide as positive features in a pavlovian appetitive discrimination task in rats. Neuropsychopharmacology 2005; 30: 731-41.
114. Palmatier MI, Bevins RA. Occasion setting by drug states: Functional equivalence following similar training history. Behav Brain Res 2008; 195: 260-70.
115. Ho BT, Huang JT. Role of dopamine in d-amphetamine-induced discriminative responding. Pharmacol Biochem Behav 1975; 3: 1085-92.
116. Schechter MD, Rosecrans JA. D-amphetamine as a discriminative cue: drugs with similar stimulus properties. Eur J Pharmacol 1973; 21: 212-6.
117. Druhan JP, Fibiger HC, Phillips AG. Influence of some drugs of abuse on the discriminative stimulus properties of amphetamine. Behav Pharmacol 1991; 2: 391-3.
118. Schechter MD, Rosecrans JA. Nicotine as a discriminative stimulus in rats depleted of norepinephrine or 5-hydroxytryptamine. Psychopharmacologia 1972; 24: 417-29.
119. Zaniewska M, McCreary AC, Sezer G, Przegalinski E, Filip M. Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol Rep 2008; 60: 645-54.
120. Stolerman IP, Pratt JA, Garcha HS, Giardini V, Kumar R. Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms. Neuropharmacology 1983; 22: 1029-37.
121. Shoaib M, Baumann MH, Rothman RB, Goldberg SR, Schindler CW. Behavioural and neurochemical characteristics of phentermine and fenfluramine administered separately and as a mixture in rats. Psychopharmacology (Berl) 1997; 131: 296-6.
122. Batman AM, Munzar P, Beardsley PM. Attenuation of nicotine's discriminative stimulus effects in rats and its locomotor activity effects in mice by serotonergic 5-HT2A/2C receptor agonists. Psychopharmacology (Berl) 2005; 179: 393-1.
123. Stolerman IP, Garcha HS. Failure of 5-HT3 antagonists and other drugs to block the nicotine discriminative stimulus. In: Harris LS Ed, Problems of Drug Dependence 1994, NIDA Research Monograph 141. Rockville, U.S. Department of Health and Human Services; 67.
124. Zaniewska M, McCreary AC, Przegalinski E, Filip M. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 2007; 571: 156-65.
125. Quarta D, Naylor CG, Stolerman IP. The serotonin 2C receptor agonist Ro-60-0175 attenuates effects of nicotine in the five-choice serial reaction time task and in drug discrimination. Psychopharmacology (Berl) 2007; 193: 391-2.
126. Hayslett RL, Tizabi Y. Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome. Pharmacol Biochem Behav 2005; 81: 879-86.
127. Schechter MD, Meehan SM. Further evidence for the mechanisms that may mediate nicotine discrimination. Pharmacol Biochem Behav 1992; 41: 807-12.
128. Young R, Bondareva T, Wesolowska A, Young S, Glennon RA. Effect of the 5-HT(6) serotonin antagonist MS-245 on the actions of (-)nicotine. Pharmacol Biochem Behav 2006; 85: 170-7.
129. Le Foll B, Wertheim CE, Goldberg SR. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci Lett 2008a; 443: 236-40.
130. Le Foll B, Justinova Z, Wertheim CE, Barnes C, Goldberg SR. Topiramate does not alter nicotine or cocaine discrimination in rats. Behav Pharmacol 2008b; 19: 13-20.
131. Takada K, Hagen TJ, Cook JM, Goldberg SR, Katz JL. Discriminative stimulus effects of intravenous nicotine in squirrel monkeys. Pharmacol Biochem Behav 1988; 30: 243-7.
132. Harris CM, Emmett-Oglesby MW, Robinson NG, Lal H. Withdrawal from chronic nicotine substitutes partially for the interoceptive stimulus produced by pentylenetetrazol (PTZ). Psychopharmacology (Berl) 1986; 90: 85-9.
133. Shearman G, Lal H. Discriminative stimulus properties of pentylenetetrazol and bemegride: some generalization and antagonism tests. Psychopharmacology (Berl) 1979; 64: 315-9.
134. Kim DJB, Brioni JD. Modulation of the discriminative stimulus properties of nicotine by diazepam and ethanol. Drug Dev Res 1995; 34: 47-54.
135. Grech DM, Willetts J, Balster RL. Pharmacological specificity of N-methyl-D-aspartate discrimination in rats. Neuropharmacology 1993; 32: 349-54.
136. Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther 2007; 321: 1127-34.
137. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13: 451-63.
138. Le Foll B, Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004; 15: 2139-43.
139. Murray JE, Wells NR, Lyford GD, Bevins RA. Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats. Psychopharmacology 2009; 205: 655-65.
140. Gasior M, Jaszyna M, Munzar P, Witkin JM, Goldberg SR. Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology (Berl) 2002; 162: 385-95.
141. Justinova Z, Ferre S, Barnes C, et al. Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology (Berl) 2009; 203: 355-67.
142. Romano C, Goldstein A, Jewell NP. Characterization of the receptor mediating the nicotine discriminative stimulus. Psychopharmacology (Berl) 1981; 74: 310-5.
143. Koek W, Slangen JL. The role of fentanyl training dose and of the alternative stimulus condition in drug generalization. Psychopharmacology (Berl) 1982; 76: 149-56.
144. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology 2003; 24: 75-82.
145. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci 2005; 25: 8593-8600.
146. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci 2006; 24: 3532-40.
147. Villegier AS, Lotfipour S, Belluzzi JD, Leslie FM. Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat. Psychopharmacology (Berl) 2007a; 193: 457-65.
148. Villegier AS, Lotfipour S, McQuown SC, Belluzzi JD, Leslie FM. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology 2007b; 52: 1415-25.
149. Wooters TE, Bardo MT. The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats. Behav Pharmacol 2007; 18: 601-8.
150. Meltzer LT, Rosecrans JA. Investigations on the CNS sites of action of the discriminative stimulus effects of arecoline and nicotine. Pharmacol Biochem Behav 1981b; 15: 21-6.
151. Shoaib M, Stolerman IP. Brain sites mediating the discriminative stimulus effects of nicotine in rats. Behav Brain Res 1996; 78: 183-8.
152. Rosecrans JA, Chance WT, Schechter MD. The discriminative stimulus properties of nicotine, d-amphetamine and morphine in dopamine depleted rats. Psychopharmacol Commun 1976; 2: 349-56.
153. Ando K, Miyata H, Hironaka N, Tsuda T, Yanagita T. The discriminative effects of nicotine and their central sites in rats. Yakubutsu Seishin Kodo 1993; 13: 129-36.
154. Miyata H, Ando K, Yanagita T. Brain regions mediating the discriminative stimulus effects of nicotine in rats. Ann N Y Acad Sci 2002; 965: 354-63.
155. Miyata H, Ando K, Yanagita T. Medial prefrontal cortex is involved in the discriminative stimulus effects of nicotine in rats. Psychopharmacology (Berl) 1999; 145: 234-6.
156. Miyata H, Ando K, Yanagita T. Studies on the involvement of the nucleus accumbens in the discriminative effects of nicotine in rats. Nippon Yakurigaku Zasshi 1991; 98: 389-97.
157. Bardo MT, Donohew RL, Harrington NG. Psychobiology of novelty seeking and drug seeking behavior. Behav Brain Res 1996; 77: 23-43.
158. Carroll ME, Anker JJ, Perry JL. Modeling risk factors for nicotine and other drug abuse in the preclinical laboratory. Drug Alcohol Depend 2009; PMID: 19136222.
159. Laviola G, Macri S, Morley-Fletcher S, Adriani W. Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neurosci Biobehav Rev 2003; 27: 19-31.
160. Philibin SD, Vann RE, Varvel SA, et al. Differential behavioral responses to nicotine in Lewis and Fischer-344 rats. Pharmacol Biochem Behav 2005; 80: 87-92.
161. Gordon TL, Meehan SM, Schechter MD. P and NP rats respond differently to the discriminative stimulus effects of nicotine. Pharmacol Biochem Behav 1993; 45: 305-8.
162. Stolerman IP, Naylor C, Elmer GI, Goldberg SR. Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology (Berl) 1999; 141: 297-6.
163. Jung ME, Wallis CJ, Gatch MB, Lal H. Sex differences in nicotine substitution to a pentylenetetrazol discriminative stimulus during ethanol withdrawal in rats. Psychopharmacology (Berl) 2000; 149: 235-40.
164. Stairs DJ, Bockman CS, Fosdick J, Mittelstet B, Schwarzkopf L. Enrichment-induced differences in nicotine drug discrimination in rats is nicotinic receptor-mediated. College on Problems of Drug Dependence Program Book 2009; 30.
165. Le Foll B, Chefer SI, Kimes AS, et al. Baseline expression of alpha4beta2* nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. Biol Psychiatry 2009; 65: 714-6.
166. Barik J, Wonnacott S. Molecular and cellular mechanisms of action of nicotine in the CNS. Handb Exp Pharmacol 2009; 173-7.
167. Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacology (Berl) 2003; 169: 1-9.
168. Coen KM, Adamson KL, Corrigall WA. Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed-and progressive-ratio schedules of reinforcement. Psychopharmacology (Berl) 2009; 201: 557-68.
169. Barrett RJ, Caul WF, Smith R. Withdrawal, tolerance, and sensitization to dopamine mediated interoceptive cues in rats trained on a three-lever drug-discrimination task. Pharmacol Biochem Behav 2005; 81: 1-8.
170. McMahon LR, Javors MA, France CP. Changes in relative potency among positive GABA(A) receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys. Psychopharmacology (Berl) 2007; 192: 135-45.
171. France CP, Gerak LR. Discriminative stimulus effects of flumazenil in rhesus monkeys treated chronically with chlordiazepoxide. Pharmacol Biochem Behav 1997; 56: 447-55.
172. Becker GL, Gerak LR, Koek W, France CP. Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys. Psychopharmacology (Berl) 2008; 201: 373-82.
173. France CP, Woods JH. Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 1989; 250: 937-43.
174. McMahon LR. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 2006; 188: 306-14.
175. George O, Ghozland S, Azar MR, et al. CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci 2007; 104: 17198-3.
176. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, Kenny PJ. Insular hypocretin transmission regulates nicotine reward. Proc Natl Acad Sci 2008; 105: 19480-5.
177. Paterson NE, Froestl W, Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 2004; 172: 179-86.